Antibodies | Frequency | OR (95% CI) | OR (95% CI) | OR (95% CI) |
---|---|---|---|---|
N (%) | Adjusted for smoking | Adjusted for HLA-SE | ||
(n = 348) | (n = 366) | |||
Anti-CCP2 | 129 (34.9) | 21.83 (12.33–38.67) | 21.69 (11.96–39.33) | 19.52 (10.96–34.79) |
Anti-CEP-1/Eno5-21 | 107 (28.9) | 6.27 (4.16–9.43) | 5.69 (3.74–8.66) | 5.57 (3.67–8.46) |
Anti-CitC1359-369 | 47 (13.1) | 3.32 (2.00–5.50) | 3.04 (1.82–5.10) | 3.27 (1.94–5.50) |
Anti-Fibα580-600 (591) | 31 (8.7) | 1.46 (0.88–2.41) | 1.39 (0.82–2.36) | 1.54 (0.91–2.61) |
Anti-Fibα563-583 (573) | 40 (10.8) | 2.20 (1.34–3.60) | 2.10 (1.25–3.53) | 2.15 (1.29–3.57) |
Anti-Fibβ62-81a (72) | 43 (11.6) | 4.06 (2.30–7.16) | 4.42 (2.47–7.91) | 3.44 (1.92–6.17) |
Anti-Fibβ62-81b (74) | 57 (15.9) | 10.68 (5.38–21.22) | 10.05 (5.02–20.10) | 9.48 (4.72–19.05) |
Anti-Fibβ36-52 | 110 (29.7) | 5.97 (4.01–8.88) | 6.07 (4.00–9.22) | 5.66 (3.76–8.51) |
Anti-CCP-1/Fil307-324 | 97 (26.2) | 11.64 (6.82–19.88) | 12.10 (6.94–21.10) | 10.39 (6.03–17.90) |
Anti-Vim60-75 | 48 (13.0) | 2.61 (1.63–4.19) | 2.37 (1.45–3.88) | 2.50 (1.54–4.08) |
Anti-Vim2-17 | 29 (7.0) | 1.90 (1.06–3.40) | 1.55 (0.85–2.85) | 1.85 (1.01–.3.39) |